GYNE-LOTRIMIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN (GYNE-LOTRIMIN).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
| Metabolism | Clotrimazole is primarily metabolized in the liver via oxidative metabolism; no specific cytochrome P450 enzymes have been identified. Following vaginal administration, systemic absorption is minimal, and the small amount absorbed is metabolized and excreted in bile and feces. |
| Excretion | Primarily fecal (approx. 90%) as unchanged drug and metabolites; renal excretion accounts for <1% of absorbed dose. |
| Half-life | The terminal elimination half-life of clotrimazole is approximately 3.5-4.9 hours. However, after topical application, systemic absorption is minimal, and local concentrations persist for hours to days at the site of action. |
| Protein binding | Clotrimazole is highly protein-bound, approximately 90-95%, primarily to albumin. |
| Volume of Distribution | Due to minimal systemic absorption after topical use, the volume of distribution is not well defined; however, after oral administration (not indicated), the Vd is approximately 10-20 L/kg, indicating extensive tissue distribution. |
| Bioavailability | After intravaginal or topical application, systemic bioavailability is extremely low (<0.5% of the applied dose). |
| Onset of Action | For intravaginal administration: onset of symptomatic relief begins within 24-72 hours after the first dose. |
| Duration of Action | With intravaginal use, clinical effects persist for 3-7 days. However, the drug is typically administered as a 1-day, 3-day, or 7-day regimen depending on formulation. |
| Molecular Weight | 344.88 |
Intravaginal: clotrimazole 500 mg vaginal tablet once or 200 mg vaginal tablet daily for 3 days or 1% vaginal cream 5 g daily for 7–14 days. Topical: clotrimazole 1% cream applied to affected area twice daily for 2–4 weeks.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children ≥12 years: same as adult dosing. Children <12 years: not recommended without physician guidance; topical formulations may be used with caution as directed. |
| Geriatric use | Same as adult dosing. No specific adjustments needed; consider potential for decreased mucosal integrity and increased sensitivity to local irritation. |
| 1st trimester | Topical clotrimazole is generally considered safe in the first trimester; absorbable azoles have been associated with risk, but minimal systemic absorption (<1-3%) reduces concern. Some guidelines recommend avoidance of intravaginal preparations in the first trimester unless necessary. |
| 2nd trimester | Safe for topical and intravaginal use with minimal systemic absorption. |
| 3rd trimester | Safe for topical and intravaginal use; may be used near term for treatment of vaginal candidiasis without known fetal risk. |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN (GYNE-LOTRIMIN).
| Placental transfer | Due to low systemic absorption (<3% after intravaginal administration), placental transfer is negligible; no significant fetal exposure expected. |
| Breastfeeding | Minimal systemic absorption after topical or intravaginal application; expected to be compatible with breastfeeding. However, avoid application to breast area to prevent infant ingestion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clotrimazole or any component of the formulation
| Precautions | Do not use if abdominal pain, fever, or foul-smelling discharge is present. Discontinue if irritation or hypersensitivity occurs. Recurrent infections may indicate underlying conditions such as diabetes or HIV. Avoid contact with eyes. For topical use only; not for ophthalmic, oral, or intravaginal use in products intended for external use. |
| Food/Dietary | No clinically significant food interactions. However, patients with diabetes should maintain glycemic control as hyperglycemia may promote yeast overgrowth. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Clotrimazole (GYNE-LOTRIMIN) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate controlled studies in pregnant women. Intravaginal use is considered safe in all trimesters, with no increased risk of major malformations or adverse fetal outcomes reported. |
| Fetal Monitoring | No specific fetal monitoring required. Standard prenatal care per guidelines. Monitor for local irritation, hypersensitivity, or superinfection. In prolonged therapy, assess for vaginal candidiasis recurrence. |
| Fertility Effects | No known adverse effects on fertility. Animal studies show no impairment of fertility at intravaginal doses. Use during pregnancy does not impact future fertility. |
| GYNE-LOTRIMIN (clotrimazole vaginal cream/tablets) is a first-line azole antifungal for uncomplicated vulvovaginal candidiasis. For recurrent cases, rule out diabetes, HIV, or antibiotic use. Advise patients to complete the full course even if symptoms resolve. Avoid concurrent use of vaginal spermicides or oil-based lubricants with latex condoms (may weaken latex). Do not use during menstruation; initiate treatment after menses. For pregnant patients, only use in second or third trimester and prefer vaginal cream over tablets. |
| Patient Advice | Use as directed for the full duration, even if symptoms improve. · Insert the cream or tablet high into the vagina at bedtime for best results. · Avoid sexual intercourse during treatment; if necessary, use a non-latex condom. · Do not use tampons, douches, or other vaginal products while on this medication. · Discontinue use and consult doctor if you experience severe abdominal pain, fever, or foul-smelling discharge. · For external itching, apply cream to the vulvar area only. · Wash hands thoroughly before and after application. |